Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.
Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand. | ...
INFORMATION PRESSERubrique : C.A. annuel 2024 Nanterre, le 12 février 2025 + 8,6% de croissance organique en 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback